Related topics: Markets, Regulation, Botanicals and Herbals, Cancer risk reduction, Cognitive function.
An article published this week by the American Botanical Council lays out the story underlying a German court's recent decision to lift a ban on kava, including the ways in which the legal goalposts moved around during the process. Kava's reinstatement, though it pertains only to the German market, is viewed a big development by an influential American observer.
"This is very important news for the market in the United States," Rick Kingston, president of regulatory and scientific affairs and senior toxicologist at SafetyCall International told NutraIngredients-USA. Kingston is also a clinical professor of pharmacy at the University of Minnesota. The article, published in ABC's HerbalEGram online newsletter, was authored by Mathias Schmidt, PhD, a pharmacist with intimate knowledge of kava (Piper methysticum) and the German market. Botanical ingredients are regulated differently there than they are in the United States, as they are classified as herbal drugs. Hence, the questions surrounding the way in which kava was first banned there and the subsequent decision to lift the ban differ from how such an action would proceed in the US.